Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways

Journal of Endocrinological Investigation

Volumn 36, Issue 11, 2013, Pages 923-930

  Long, H D ^a   Lin, Y E ^a   Liu, M J ^a   Liang, L Y ^a   Zeng, Zhao Hua ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Aldosterone; Metabolic syndrome; Mitogen activated protein kinase; Phosphatidylinositol 3 kinase Akt; Spironolactone

Indexed keywords

ALDOSTERONE; GLUCOSE; INSULIN; LIPID; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 11; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM ION; PROTEIN KINASE B; SODIUM ION; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME PHOSPHORYLATION; HOMEOSTASIS MODEL ASSESSCRITICAL OF INSULIN RESISTANCE; HYPERTENSION; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; RAT; WESTERN BLOTTING;

ALDOSTERONE; ANIMALS; APOPTOSIS; DIET, HIGH-FAT; DYSLIPIDEMIAS; HYPERTENSION; INSULIN-SECRETING CELLS; MALE; MAP KINASE SIGNALING SYSTEM; METABOLIC SYNDROME X; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; RECEPTORS, MINERALOCORTICOID; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE;

EID: 84891670849     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8946     Document Type: Article

References (36)

1. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005, 112: 666-73.
2. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 2: 1595-607.
3. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005, 10: 7-13.
4. Krug AW, Stelzner L, Rao AD, Lichtman AH, Williams GH, Adler GK. Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. Metabolism 2013, 62: 386-91.
5. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992, 71: 169-80.
6. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37: 1047-52.
7. Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 2010, 57: 12-25.
8. Funder JW, Feldman D, Edelman IS. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 1973, 92: 994-1004.
9. Bentley-Lewis R, Adler G, Perlstein T, et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007, 92: 4472-5.
10. Shimamoto K, Shiiki M, Ise T, et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism ? J Hum Hypertens 1994, 8: 755-9.
11. Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 1999, 60: 401-5.
12. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 1999, 7: 355-62.
13. Leung PS, de Gasparo M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. J Cardiometab Syndr 2006, 1: 197-203.
14. Fujita T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 2010, 55: 813-8.
15. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004, 53: 2735-40.
16. Callera GE, Touyz RM, Tostes RC, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005, 45: 773-9.
17. Chen C, Liang W, Jia J, van Goor H, Singhal PC, Ding G. Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and p38MAPK signaling pathways. Nephron Exp Nephrol 2009, 113: 26-34.
18. Widmann C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999, 79: 143-80.
19. Alvarado-Kristensson M, Porn-Ares MI, Grethe S, Smith D, Zheng L, Andersson T. p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase activities have opposite effects on human neutrophil apoptosis. FASEB J 2002, 16: 129-31.
20. Zeng ZH, Luo BH, Gao YJ, et al. Control of vascular changes by renin- angiotensin-aldosterone system in salt-sensitive hypertension. Eur J Pharmacol 2004, 503: 129-33.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
22. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB. Assay for redox-sensitive transcription factor. Methods Enzymol 2000, 319: 585-602.
23. Ding G, Franki N, Kapasi AA, Reddy K, Gibbons N, Singhal PC. Tubular cell senescence and expression of TGF-beta1 and p21(WAF1/CIP1) in tubulointerstitial fibrosis of aging rats. Exp Mol Pathol 2001, 70: 43-53.
24. Hayden MR, Sowers JR. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 2008, 3: 129-31.
25. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-17.
26. Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005, 46: 425-31.
27. Pitt B, Remme W, Zannad F, et al. The eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348: 1309-21.
28. Sowers JR, Whaley-Connell A, Epstein M. Narrative Review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 11: 776-83.
29. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-γ, and proinflammatory adipokines. Circulation 2008, 17: 2253-61.
30. Lastra G, Whaley-Connell A, Manrique C, et al. Low-dose SPL reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008, 1: 110-6.
31. Yuan L, Li X, Xu GL, Qi CJ. Effects of renin-angiotensin system blockade on islet function in diabetic rats. J Endocrinol Invest 2010, 33: 13-9.
32. Farman N, Bocchi B. Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000, 57: 1364-9.
33. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242: 583-5.
34. Draper N, Stewart PM. 11β-hydroxysteroid dehydrogenase and the prereceptor regulation of corticosteroid hormone action. J Endocrinol 2005, 186: 251-71.
35. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol 2005, 186: 1-20.
36. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 2005, 96: 643-50.